Subsidiary of Indian drug firm pleads guilty, agrees to $500 million penalty

The Associated Press/Washington Post: Subsidiary Of Indian Drug Maker Agrees To Pay Record $500 Million US Penalty For Impure Drugs
A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S. Federal prosecutors say the guilty plea by Ranbaxy USA Inc. represents the largest financial penalty against a generic drug company for violations of the Federal Food, Drug and Cosmetic Act, which prohibits the sale of impure drugs (5/13).